DBV Technologies welcomes Charles Ruban as Chief Development Officer

Bagneux, France, May 10, 2012 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the reinforcement of its team management with the arrival of Mr. Charles Ruban – starting May 30- as Chief Development Officer, supervising all development activities, from CMC to clinical trials and regulatory activities. Charles will be a member of the Executive Committee.

Pierre-Henri Benhamou, M.D., Chairman and CEO said: “We are very enthused to have Charles Ruban join DBV’s management team. Charles will bring to the Company considerable expertise, notably in terms of product development and project management. DBV Technologies now has the key building blocks in place to accelerate its development, opening up a decisive new approach to the treatment of allergy – a major public health issue unfortunately constantly growing in prevalence.”

Prior to joining DBV Technologies, Charles Ruban was Senior VP, Product Development at Stallergènes, member of the Executive Committee. After a 9 years european experience in management consulting for Europroup, Charles has spent 10 years at Stallergènes. He started heading Supply Chain management, and evolved as R&D Program Director before moving to his leadership role. Charles has been instrumental in developing the global Allergen tablet program named Stalair®, which led to the launch of Oralair® in Europe, other allergen development in the US and the conduction of a joint development program in Japan with Shionogi. Charles graduated from Ecole Centrale de Lyon, concluded his Master of Science in Biomedical Engineering at Harvard-M.I.T. Division of Health Sciences and Technology and holds an Executive MBA from INSEAD.

About DBV Technologies:

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has designed two products: Viaskin® Peanut and Viaskin® Milk. The development clinical program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Contacts

David Schilansky
Chief Financial Officer
DBV Technologies
Tél. : +33(0)1 55 42 78 75
david.schilansky@dbv-technologies.com

NewCap.
Financial Communication and investor relations
Emmanuel Huynh / Alexandra Schiltz
Tél. : +33(0)1 44 71 94 94
dbv@newcap.fr

Ronald Trahan, APR
Press relations
Ronald Trahan
Tél. : +1 508 359 4005
rctrahan@ronaldtrahan.com